CCM
LCTX icon

Chilton Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Chilton Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-400
Closed -$1K – 435
2021
Q4 		$1K Buy
+400
New +$936 ﹤0.01% 631

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Chilton Capital Management's LCTX Position: Q1 2022 in Review

Chilton Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q1 2022, closing a stake of 400 shares — an estimated $1K sold.

Chilton Capital Management first reported a position in LCTX in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 110 funds tracked by Wall St. Rank hold LCTX as of Q1 2022.

  • Chilton Capital Management reported no remaining Lineage Cell Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Chilton Capital Management sold 400 Lineage Cell Therapeutics shares in Q1 2022, an estimated $1K.
  • Chilton Capital Management first reported a position in Lineage Cell Therapeutics in Q4 2021 and held it in 1 quarter.
  • Chilton Capital Management's Lineage Cell Therapeutics position peaked at $1K in Q4 2021.
  • 110 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2022.

Based on Chilton Capital Management's 13F filing for Q1 2022, filed 16 May 2022.